Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Oleksandr Voitko"'
Autor:
Jonathan W. Goldman, Francesco Verderame, T. Dalvi, D. Trukhin, A. Poltoratskiy, Y. Chen, Oleksandr Voitko, Nikolay Conev, H. Jiang, György Losonczy, Luis Paz-Ares, Mustafa Ozguroglu, I. Bondarenko, Niels Reinmuth, Helen Broadhurst, Katsuyuki Hotta, Galina Statsenko, Libor Havel, J.H. Ji, Maximilian Hochmair
Publikováno v:
Annals of Oncology. 32:S1338
Autor:
A. Franks, Niels Reinmuth, Yashaswi Shrestha, Marina Chiara Garassino, Katsuyuki Hotta, A. Poltoratskiy, D. Trukhin, Galina Statsenko, Igor Bondarenko, Jonathan W. Goldman, Haruhiro Saito, Oleksandr Voitko, Maximilian Hochmair, Stephanie Jones, Y. Chen, Nikolay Conev, Stuart Spencer, Mingchao Xie, J.H. Ji, Luis Paz-Ares, Mustafa Ozguroglu
Publikováno v:
Annals of Oncology. 32:S289
Autor:
Maximilian Hochmair, Nikunj Patel, M. Dvorkin, Libor Havel, Katsuyuki Hotta, M.C. Garassino, J.H. Ji, Jonathan W. Goldman, H. Jiang, A. Poltoratskiy, Y. Chen, Helen Mann, D. Trukhin, Yashaswi Shrestha, Niels Reinmuth, György Losonczy, Luis Paz-Ares, Mustafa Ozguroglu, Galina Statsenko, Oleksandr Voitko
Publikováno v:
Publons
Background In the phase III CASPIAN trial, durvalumab (D) in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved the primary endpoint of OS vs EP alone in pts with extensive-stage small-cell lung cancer (ES-SCL
Autor:
Francesco Verderame, Galina Statsenko, Libor Havel, Jonathan W. Goldman, Y. Chen, György Losonczy, A. Lloyd, Y. Zheng, A. Poltoratskiy, D. Trukhin, Haiyi Jiang, J.H. Ji, M. Dvorkin, Niels Reinmuth, Katsuyuki Hotta, Maximilian Hochmair, M. Thomas, Luis Paz-Ares, Mustafa Ozguroglu, Oleksandr Voitko
Publikováno v:
Annals of Oncology. 30:xi66
Background CASPIAN is a phase 3, open-label study of 1L platinum-etoposide (EP) ± durvalumab (D) ± tremelimumab (T) for pts with ES-SCLC. D+EP significantly improved OS vs EP alone (HR 0.73 [95% CI 0.59–0.91]; p = 0.0047) at a planned interim ana